BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Femia D, Prinzi N, Anichini A, Mortarini R, Nichetti F, Corti F, Torchio M, Peverelli G, Pagani F, Maurichi A, Mattavelli I, Milione M, Bedini N, Corti A, Di Bartolomeo M, de Braud F, Pusceddu S. Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. Target Oncol 2018;13:567-82. [PMID: 30073632 DOI: 10.1007/s11523-018-0585-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Giannetta E, La Salvia A, Rizza L, Muscogiuri G, Campione S, Pozza C, Colao AAL, Faggiano A. Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms? Front Endocrinol (Lausanne) 2021;12:672499. [PMID: 34367064 DOI: 10.3389/fendo.2021.672499] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
2 Albertelli M, Dotto A, Nista F, Veresani A, Patti L, Gay S, Sciallero S, Boschetti M, Ferone D. "Present and future of immunotherapy in Neuroendocrine Tumors". Rev Endocr Metab Disord 2021;22:615-36. [PMID: 33851319 DOI: 10.1007/s11154-021-09647-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
3 Weppler AM, Pattison A, Bhave P, De Ieso P, Raleigh J, Hatzimihalis A, Gill AJ, Balachander S, Callahan J, Chua M, Au-Yeung G, McArthur GA, Hicks RJ, Tothill RW, Sandhu S. Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma. J Immunother Cancer 2020;8:e000700. [PMID: 33060145 DOI: 10.1136/jitc-2020-000700] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
4 Chandra S, Zheng Y, Pandya S, Yu T, Kearney M, Wang L, Kim R, Phatak H. Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy. Future Oncol 2020;16:2521-36. [PMID: 32883109 DOI: 10.2217/fon-2020-0453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Cappabianca L, Guadagni S, Maccarone R, Sebastiano M, Chiominto A, Farina AR, Mackay AR. A pilot study of alternative TrkAIII splicing in Merkel cell carcinoma: a potential oncogenic mechanism and novel therapeutic target. J Exp Clin Cancer Res 2019;38:424. [PMID: 31640749 DOI: 10.1186/s13046-019-1425-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
6 Guadagni S, Chiominto A, Mackay AR, Farina AR, Cappabianca L, Puccica I, Valiyeva S, Clementi M. Advanced Merkel cell carcinoma of the lower extremity treated with surgery and isolated pelvic and limb perfusion using Melphalan: A case of unexpected long-term survival. Int J Surg Case Rep 2019;61:4-8. [PMID: 31302319 DOI: 10.1016/j.ijscr.2019.06.064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
7 Llombart B. The Rising Incidence of Merkel Cell Carcinoma. Actas Dermosifiliogr (Engl Ed) 2019;110:337. [PMID: 30797522 DOI: 10.1016/j.ad.2018.10.011] [Reference Citation Analysis]